Clinical medicine profile
Mycophenolate Mofetil
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- GIT diseases
- live attenuated vaccines
- complete blood count performed as follows - weekly during the 1st month, twice monthly for the 2nd and the 3rd month of treatment, then monthly through the 1st yr
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Cardiac:1.5 gm BD [in combination with cyclosporine and corticosteroids]. Renal: 1 gm BD in combination with cyclosporine and corti- costeroids].
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Prophylaxis of acute renal or cardiac transplant rejection.
- It is used in combination with cyclosporine and corticosteroids.
- Clinical selection for Mycophenolate Mofetil should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Therapeutic agent (verify pharmacological class).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- chest pain
- dysp- nea
- hematuria
- hypertension
- leukopenia
- neu- tropenia
- infections
- peripheral edema
- arthralgia joint pain
- GI haemorrhage
- gingival hyperplasia
- neutropenia
- oral moniliasis
- pancreatitis
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
It is metabolized to mycophenolic acid, which is a selective, noncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase.
Read complete mechanism
It is metabolized to mycophenolic acid, which is a selective, noncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase. The de novo synthesis pathway of guanosine nucleotides is inhibited without being incorporated into DNA. Its selectivity is due to the fact that T and B-lymphocytes are almost solely dependent for their proliferation on the inhibited de novo synthesis of purines, while other cell types can utilize salvage pathways.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| Mofecon-C 250 | Concord Biotech LTD. | Capsule, Hard | Unavailable |
| PHENOLATE TABLETS | MEDCURE HEALTHCARE LTD | Tablet | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.